68 Results

People

  1. Levine
    Levine
  2. Abdel-Wahab
    Abdel-Wahab
  3. Perales
    Perales
  4. Van Den Brink
    Van Den Brink
  5. Younes
    Younes
  6. Young
    Young
  7. Kernan
    Kernan
  8. Papadopoulos
    Papadopoulos
  9. Tallman
    Tallman
  10. Castro-Malaspina
    Castro-Malaspina

Groups

  1. Center for Hematologic Malignancies (68)
  2. Executive Committee, Center for Hematologic Malignancies (68)
  3. Department of Medicine (66)
  4. Hematologic Malignancies, Division of (64)
  5. GSK Faculty (59)
  6. Human Oncology and Pathogenesis Program (45)
  7. Tow Center for Developmental Oncology (TCDO) (37)
  8. Epidemiology and Biostatistics (29)
  9. Adult Leukemia (28)
  10. Sloan Kettering Institute Faculty (26)
  1. "middle aged"
  2. "Executive Committee, Center for Hematologic Malignancies"
Formats
  1. Journal Article (64)
  2. Research Letter (3)
  3. Review (1)
Groups
  1. Center for Hematologic Malignancies (68)
  2. Executive Committee, Center for Hematologic Malignancies (68)
  3. Department of Medicine (66)
  4. Hematologic Malignancies, Division of (64)
  5. GSK Faculty (59)
  6. Human Oncology and Pathogenesis Program (45)

More Groups

People
  1. Ross Levine (25)
  2. Omar Abdel-Wahab (19)
  3. Marcel Van Den Brink (17)
  4. Miguel-Angel Perales (14)
  5. Anas Younes (10)
  6. James Young (10)

More People

Years
  1. 2024 (1)
  2. 2023 (6)
  3. 2022 (4)
  4. 2021 (3)
  5. 2020 (6)
  6. 2019 (4)

More Years

Publications
  1. Blood (9)
  2. Biology of Blood and Marrow Transplantation (8)
  3. Blood Advances (8)
  4. Leukemia (6)
  5. New England Journal of Medicine (6)
  6. British Journal of Haematology (3)

More Publications

Publishers
  1. American Society of Hematology (17)
  2. Nature Publishing Group (9)
  3. Elsevier Inc. (8)
  4. Massachusetts Medical Society (6)
  5. Elsevier Science, Inc. (4)
  6. American Society of Clinical Oncology (3)

More Publishers

Results (68)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Diffuse large B-cell lymphoma involving osseous sites: Utility of response assessment by PET/CT and good long-term outcomes
    Journal Article

    Ghione, P.; Ahsanuddin, S.; Luttwak, E.; Varela, S. B.; Nakajima, R.; Michaud, L.; Gupta, K.; Navitski, A.; Straus, D.; Palomba, M. L.; more...
    Haematologica (2024)

    Fulltext@MSK | Save
  • Mutant PIK3CA is a targetable driver alteration in histiocytic neoplasms
    Journal Article

    Durham, B. H.; Hershkovitz-Rokah, O.; Abdel-Wahab, O.; Yabe, M.; Chung, Y. R.; Itchaki, G.; Ben-Sasson, M.; Asher-Guz, V. A.; Groshar, D.; Doe-Tetteh, S. A.; more...
    Blood Advances (2023)

    Fulltext@MSK | Save
  • Outcomes after interruption of targeted therapy in patients with histiocytic neoplasms
    Journal Article

    Reiner, A. S.; Durham, B. H.; Yabe, M.; Petrova-Drus, K.; Francis, J. H.; Rampal, R. K.; Lacouture, M. E.; Rotemberg, V.; Abdel-Wahab, O.; Panageas, K. S.; more...
    British Journal of Haematology (2023)

    Fulltext@MSK | Save
  • Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master Trial
    Journal Article

    Duong, V. H.; Ruppert, A. S.; Mims, A. S.; Borate, U.; Stein, E. M.; Baer, M. R.; Stock, W.; Kovacsovics, T.; Blum, W.; Arellano, M. L.; more...
    Cancer (2023)

    Fulltext@MSK | Save
  • Pevonedistat with azacitidine in older patients with TP53-mutated AML: A phase 2 study with laboratory correlates
    Research Letter

    Saliba, A. N.; Kaufmann, S. H.; Stein, E. M.; Patel, P. A.; Baer, M. R.; Stock, W.; Deininger, M.; Blum, W.; Schiller, G. J.; Olin, R. L.; more...
    Blood Advances (2023)

    Fulltext@MSK | Save
  • High-resolution analyses of associations between medications, microbiome, and mortality in cancer patients
    Journal Article

    Nguyen, C. L.; Markey, K. A.; Miltiadous, O.; Dai, A.; Waters, N.; Sadeghi, K.; Fei, T.; Shouval, R.; Taylor, B. P.; Liao, C.; more...
    Cell (2023)

    Fulltext@MSK | Save
  • Molecularly targeted epigenetic therapy with mocetinostat in relapsed and refractory non-Hodgkin lymphoma with CREBBP or EP300 mutations: An open label phase II study
    Research Letter

    Qualls, D.; Noy, A.; Straus, D.; Matasar, M.; Moskowitz, C.; Seshan, V.; Dogan, A.; Salles, G.; Younes, A.; Zelenetz, A. D.; more...
    Leukemia and Lymphoma (2023)

    Fulltext@MSK | Save
  • Single-cell multi-omics of human clonal hematopoiesis reveals that DNMT3A R882 mutations perturb early progenitor states through selective hypomethylation
    Journal Article

    Nam, A. S.; Dusaj, N.; Izzo, F.; Murali, R.; Myers, R. M.; Mouhieddine, T. H.; Sotelo, J.; Benbarche, S.; Waarts, M.; Gaiti, F.; more...
    Nature Genetics (2022)

    Fulltext@MSK | Save
  • De Novo myelodysplastic syndromes in patients 20–50 years old are enriched for adverse risk features
    Journal Article

    Epstein-Peterson, Z. D.; Spitzer, B.; Derkach, A.; Arango, J. E.; McCarter, J. G. W.; Medina-Martínez, J. S.; McGovern, E.; Farnoud, N. R.; Levine, R. L.; Tallman, M. S.
    Leukemia Research (2022)

    Fulltext@MSK | Save
  • Mechanisms of resistance to noncovalent Bruton's tyrosine kinase inhibitors
    Journal Article

    Wang, E.; Mi, X.; Thompson, M. C.; Montoya, S.; Notti, R. Q.; Afaghani, J.; Durham, B. H.; Penson, A.; Witkowski, M. T.; Lu, S. X.; more...
    New England Journal of Medicine (2022)

    Fulltext@MSK | Save